title: [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
abstract: OBJECTIVE
  To evaluate efficacy and safety of second-generation tyrosine kinase inhibitors (TKI) dasatinib, nilotinib and imatinib in treatment of newly diagnosed patients with chronic-phase chronic myeloid leukemia (CML).
  
  
  METHODS
  The clinical data and follow-up results of 163 patients with chronic-phase chronic myeloid lenkemia(CP-CML) who were treated in our hospital during the nearly 3 years were analysed retrospectively, among 163 patients 47 received dasatinib, 43 received nilotinib and 73 received imatinib. The efficacy, disease progression and safety were evaluated.
  
  
  RESULTS
  After treatment for 3 months, the rate of complete hematologic response(CHR) in three treatment groups were 77%, 79% and 67%, respectivily, CHR at 12 months in three treatment groups were 92%, 91% and 90%, respectively. By 3 months, the rates of complete cytogenetic response(CCyR) with dasatinib and nilotinib were higher than that with imatinib (55%, 53% vs 33%)(P<0.05 for both comparisons), CCyR at 12 months in three treatment groups were 86%, 88% vs 69% (P<0.05 for both comparisons). The rates of major molecular response(MMR) for dasatinib (11%) and nilotinib (9%) by 3 months were significantly higher than that for imatinib (1%) (P<0.05 for both comparisons), MMR at 12 months in three treatment groups were 49%, 50% and 28%, respectively (P<0.05 for both comparison). Progression to the accelerated or blast phase of CML occurred in 2 (4%) patients received dasatinib, 2 (5%) received nilotinib and 6 (8%) received imatinib. The safety profiles of these 3 second-generation TKI treatments were similar.
  
  
  CONCLUSIONS
  Both dasatinib and nilotinib induced strikingly higher and faster rates of complete cytogenetic response and major molecular response, with a statistically significant difference from imatinib.
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Ya-Yun
authors.initials: YY
authors.lastname: Wang
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China. E-mail: zhao6201@126.com.
authors.forename: Hong-Guo
authors.initials: HG
authors.lastname: Zhao
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Zhong-Guang
authors.initials: ZG
authors.lastname: Cui
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Guang-Lun
authors.initials: GL
authors.lastname: Li
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Shi
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Xu
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Hematolagy, The Aftiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China.
authors.forename: Teng
authors.initials: T
authors.lastname: Zhao
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001752:Blast Crisis; D000069439:Dasatinib; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib